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Background: ERBB3 binding protein 1 (EBP1) gene transfer into human salivary adenoid cystic carcinoma cells has
been shown to significantly inhibit cell proliferation and reduce tumor metastasis in mouse models. In the current
study, to evaluate if EBP1 is a novel biomarker capable of identifying patients at higher risk of disease progression
and recurrence, we examined the EBP1 expression profile in adenoid cystic carcinoma (ACC) patients and analyzed
its clinicopathological relevance. To understand the underlying anti-metastatic mechanism, we investigated if EBP1
regulates invasion-related molecules.
Methods: We performed immunohistochemical analysis on 132 primary adenoid cystic carcinoma and adjacent
non-cancerous tissues using commercial EBP1, MMP9, E-cadherin and ICAM-1 antibodies. Results were correlated to
clinicopathological parameters, long-term survival and invasion-related molecules by statistical analysis. Cell motility
and invasiveness of vector or wild-type EBP1-transfected ACC-M cell lines were evaluated using wound healing and
Boyden chamber assays. MMP9, E-cadherin and ICAM-1 proteins in these cell lines were detected using western
blot assay.
Results: The expression of EBP1 was significantly higher in non-cancerous adjacent tissues compared with
corresponding cancer tissues. The intensity and percentage of cells that reacted with EBP1 antibodies were
significantly higher in cases with tubular pattern than those with solid pattern (P<0.0001). We also found adenoid
cystic carcinoma with local lymphatic metastasis had significantly lower EBP1 expression than ACC with no local
lymphatic node metastasis (P<0.0001). Similar findings were observed in ACC with lung metastasis compared with
cases with no lung metastasis (P<0.0001), in particular, in cases with perineural invasion compared with cases with
no perineural invasion (P<0.0001). Furthermore, a decrease in EBP1 expression was positively associated with a
reduction in overall survival of ACC patients. Of note, EBP1 inhibits migration and invasiveness of ACC cells by
upregulating E-cadherin but downregulating MMP9. In clinical adenoid cystic carcinoma patients, higher EBP1
expression was positively correlated with E-cadherin levels (P<0.001) but negatively correlated with MMP9
expression (P=0.0002).
Conclusions: EBP1 expression is reduced in adenoid cystic carcinoma, indicating unfavorable prognosis of ACC
patients. Its regulation of MMP9 and E-cadherin protein levels suggests a critical therapeutic potential.* Correspondence: yuyoucheng@yahoo.com
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Adenoid cystic carcinoma (ACC) of the major and
minor salivary glands is a relatively rare epithelial tumor
[1-3]. However, ACCs are highly aggressive neoplasms
with a predilection for perineural infiltration, which par-
tially explains the tendency for local recurrence [1,2].
Unlike squamous cell carcinoma in the head and neck,
ACC often spreads systemically to lungs and bone, lead-
ing to a 20-year survival rate of only about 11% [1-3].
Therefore, it will be of great clinical value to identify the
molecular events associated with the development and
progression of ACC for early detection and prognosis, in
particular the targets for therapeutic treatment [4].
ERBB3 binding protein 1 (EBP1) is the human
homologue of a previously identified cell cycle-regulated
mouse protein p38-2G4 [5]. EBP1 is a conserved mol-
ecule across species with multiple roles in cell prolifera-
tion and differentiation [6-10]. In our previous study, we
demonstrated that wild-type EBP1 gene transfer into
human salivary adenoid cystic carcinoma cells signifi-
cantly inhibits cell proliferation in in vitro assays, and
most importantly, reduces tumor metastatic potential in
an experimental metastatic mouse model [11], consistent
with its inhibitory property identified in cancers of glan-
dular epithelial origin such as prostate [12,13] and breast
[14]. In this study, we investigated the EBP1 expression
profile in adenoid cystic carcinoma patients to evaluate
if EBP1 is a novel biomarker capable of identifying
patients at higher risk of disease progression and recur-
rence. Our results suggest that EBP1 immunoreactivity
inversely correlates with local invasion and distant
spread of adenoid cystic carcinomas. Patients with lower
EBP1 levels had poorer long-term survival than those
with higher EBP1 expression.Methods
Patients and specimens
Formalin-fixed, paraffin-embedded specimens were ran-
domly selected from the primary tumor and adjacent non-
cancerous tissues of 66 patients suffering from operable
ACCs and thus undergoing curative surgery at the Ninth
People’s Hospital, JiaoTong University from 2004 to 2007.
All archival blocks were stored at room temperature in a
modern centrally air-conditioned histology laboratory.
None of the cases had received pre-operative chemother-
apy or radiotherapy. Histopathological grading of ACCs
was performed according to WHO classification [15], and
tumor staging was based on the tumor-node-metastasis
(TNM) system [16]. Medical records and prognostic
follow-up data were obtained from the patient database
completed by physicians and data managers after each pa-
tient visit. Independent Ethics Committee of Shanghai
Ninth People’s Hospital affiliated to Shanghai JiaoTongUniversity, School of Medicine approved the study proto-
col (Number 201287).Immunohistochemistry (IHC)
Hematoxylin and eosin (H&E) sections were analyzed
for the presence of tumors. Sections containing the high-
est number of tumors were selected for each patient.
The corresponding tissue blocks were then recut into
5-μm thick sections and mounted on charged slides. The
sections were deparaffinized in toluene and rehydrated
in a gradient series of ethanol. Endogenous peroxides
were quenched by treatment with 0.3% H2O2/methanol
for 30 min at room temperature. Antigen retrieval was
accomplished by microwave heating at 90°C for 15 min
in citrate buffer (10 mM, pH 6.0). Slides were incubated
with rabbit polyclonal anti-EBP1 antibody (EMD Milli-
pore Corporation, Billerica, MA, USA), MMP9 rabbit
polyclonal antibody, E-cadherin rabbit mAb, ICAM-1
rabbit polyclonal antibody (Cell Signaling Technology,
Inc., Danvers, MA, USA) following immunohistochemis-
try protocols provided by the manufacturers. Specific
staining was detected by applying the Vectastain Elite
ABC Kit (Vector Laboratories). For negative control, tis-
sues were incubated with non-immunized purified rabbit
IgG (EMD Millipore Corporation, Billerica, MA, USA).Evaluation of immunostaining
Two independent pathologists examined randomly
selected 10 fields per stained section, and two sections
for each specimen using light microscope at 40× magni-
fication. The percentage of cells with positive EBP1stain-
ing was semi-quantitatively assessed using a four-tiered
scoring system: negative (−), <5% positive cells; inter-
mediate (+), 5–25%; moderate (++), 25–50% and strong
(+++), 50–100% of cells stained.Cell culture
The generation of ACC-M cell lines stably transfected with
EBP1 cDNA or a vector control was previously described
[11]. We used ACC-M, ACC-M0 (ACC-M-pcDNA3.1)
and ACC-M1 (ACC-M-EBP1-1μg) as Control, Vector
and ebp1.Western blotting
Western blot analysis was performed as previously
described [11]. Antibody against GADPH was purchased
from Sigma. Specific antibodies for EBP1, MMP9,
ICAM-1 and E-cadherin were the same as those used
for immunohistochemistry analysis. We followed the
protocols provided by the manufacturers for the concen-
tration of these antibodies in Western blot analysis.
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A modified Boyden chamber assay was used to deter-
mine cell invasion, as described previously [13]. In brief,
culture plate inserts (8-um pore size and 12-mm diam-
eter, Millicell-PCF) were coated with 150 μl PBS con-
taining 10 μg collagen and 1μg fibronectin (BD
Bioscience) for 1 h at room temperature before adding
cells suspended in 450 μl RPMI 1640 medium with 5%
charcoal-striped serum. The bottom wells of the system
were filled with 600 μl complete medium. After 24 h in
a humidified atmosphere of 5% CO2 in air, the inserts
were fixed in 10% formalin for 30 min and after washing
with PBS, stained with 0.5% crystal violet in 25% metha-
nol for 45 min. Non-migrating cells on the top of the
filters were removed with a cotton swab. Cells that had
migrated to undersurface of the filter were examined at
20× magnification. The number of cells in three repre-
sentative areas was counted. Each experiment was per-
formed in triplicate.
Wound healing assay
The assay was performed as described previously [17].
Briefly, cells were seeded in six-well plates at a density of
5×106 cells/well and grown to confluence. The mono-
layer culture was then artificially scrape-wounded with a
sterile micropipette tip to create a denuded zone (gap)
of constant width. After the detached cells were removed
with serum-free RPMI 1640, cells that had migrated to
the wounded region were observed by Olympus CK-2
inverted microscope and photographed (100× magnifica-
tion). The resulting images were compiled in Adobe
Photoshop. The wound areas were measured by the pro-
gram Image J (http://rsb.info.nih.gov.proxy-hs.research-
port.umd.edu/ij/). Average migration speed was
calculated from the average distance traveled and the
time elapsed between images.
Statistical analysis
Associations were evaluated with Fisher’s exact test,
Wilcoxon test, Kruskal Wallis test and Spearman rank
correlation test. Survival analysis was carried out using
Kaplan–Meier estimates, log rank tests and Cox’s pro-
portional hazards regression analysis. All tests were
two-sided, and the significance level was set at 5%. All of
the statistical analysis was performed using SPSS 13.0
software (SPSS Inc, Chicago, IL, USA).
Results
Immunohistochemical staining of EBP1 expression in
ACCs
To evaluate if EBP1 status is linked to the clinical progres-
sion of ACC, immunohistochemistry analysis was per-
formed to examine EBP1 protein expression in 132
paraffin-embedded normal adjacent and carcinomatissues. Examples of immunohistochemical stains in differ-
ent types of ACC and adjacent non-cancerous tissues with
rabbit polyclonal anti-human EBP1 antibody are shown in
Figure 1. In ACC, EBP1 staining was localized predomin-
antly to the cytoplasm of epithelial cells of glands, whereas
in the adjacent non-cancerous tissues, abundant EBP1
immunoreactivity was observed in both the cytoplasm and
nuclei. Incubation with purified normal rabbit polyclonal
IgG did not result in any staining in adjacent non-
cancerous tissues, indicating the specificity for EBP1.
Among 66 ACC tissues (Table 1), 56 showed positive
EBP1 staining (84.9%) with variable staining intensity.
Scores were “-” in 10 cases, “+” in 9 cases (13.6%), “++” in
24 cases (36.4%) and “+++” in 23 cases (34.9%). In con-
trast, the proportion of positive EBP1 staining (98.49%)
was significantly higher in non-cancerous adjacent tissues
compared with corresponding cancer tissues (P=0.0402),
with 17 cases (25.8%) scored as “+”, 3 cases (4.6%) as “++”
and 45 cases (68.2%) as “+++”, indicating EBP1 is
decreased in the progression of ACC.Relationship between EBP1 expression and
clinicopathological parameters
The results of the immunohistochemical analysis of
EBP1 staining intensity were further statistically analyzed
to determine the relationship between EBP1 intensity
and clinicopathological variables. As shown in Table 2,
there was no significant association of EBP1 staining
level with age at diagnosis (P=0.1597) and gender
(P=0.6956). However, EBP1 expression status was signifi-
cantly correlated with histology subtype (P=0.00005).
The intensity and percentage of cells that reacted with
EBP1 antibodies were significantly higher in cases with
tubular pattern than that with solid pattern (P<0.0001),
although there was no significant correlation of EBP1
immunoreactivity in cases with solid pattern compared
with that with cribriform pattern (P=0.6393) or similarly,
tubular vs cribriform type (P=0.2075). Interestingly, we
found ACC with local lymphatic metastasis had a signifi-
cantly lower percentage of EBP1 expression than ACC
with no local lymphatic node metastasis (42% versus
94%, P<0.0001). Similar findings were observed in ACC
with distant lung metastasis compared with cases with
no lung metastasis (50% versus 94%, P<0.0001), particu-
larly in cases with perineural invasion compared with
cases with no perineural invasion (60.9% versus 95.4%,
P<0.0001). In addition, in early clinical stages (Table 2,
T1–2), 92.8% samples of human ACC tissues examined
were immunohistochemically stained with antibody
against EBP1 with advanced disease (Table 2, T3–4), and
only 70.8% tissues retained EBP1 staining. The reduced





Figure 1 Detection of EBP1 in ACC and adjacent non-cancerous tissues by immunohistochemical staining. Representative sections of
solid (A1), tubular (B1) and cribriform (C1) patterns of ACCs showing intermediate (+) EBP1 staining (×40). Strongly positive staining (+++) was
observed in adjacent non-cancerous tissues (A2, B2 and C2, 40). The same adjacent non-cancerous tissues (A3, B3 and C3) incubated with
concentration-matched non-immune rabbit IgG showed no staining. Magnification of relevant parts of the images are included as insets.
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Cellular migration is one of fundamental features of can-
cer metastasis. To confirm the anti-metastatic potential
of EBP1 based on the relationship between EBP1 expres-
sion and clinicopathological parameters, wound-healing
assays were first performed to examine the effect of
EBP1 on the migratory features of ACC cells. Control
cells migrated toward the scratched region, resulting in
‘wound healing’ with a narrow margin. On the other
hand, cells transfected with EBP1 cDNA inhibited the
migration of cells (Figure 2A).Table 1 Expression of Ebp1 in ACC and matched para-carcino




P value 0.0402In further experiments examining the invasiveness of
tumor cells, we found that parental and control vector-
transfected tumor cells efficiently penetrated the
Matrigel-coated membrane, whereas the penetration rate
of EBP1-transfected tumor cells was significantly
reduced (Figure 2B).
To explore the mechanism of anti-invasiveness action
of EBP1, we detected the effect of EBP1 on the expres-
sion of invasion-related factors. Extracellular matrix re-
modeling proteinases such as matrix metalloproteinases
(MMPs) play a principal role in altering the localma tissues
+++ No. of negatives (%)
) 23(34.85%) 10(15.15%)
45(68.18%) 1(1.52%)
Table 2 Relationship between Ebp1 expression and clinicopathological features of ACC patients
Variables N (%) - + ++ +++ p-value
Age at diagnosis <=50 27 1(3.70%) 6(22.22%) 8(29.63%) 12(44.44%) 0.1597
>50 39 9(23.08%) 3(7.69%) 16(41.03%) 11(28.21%)
Gender Male 33 4(12.12%) 5(15.15%) 12(36.36%) 12(36.36%) 0.6956
Female 33 6(18.18%) 4(12.12%) 12(36.36%) 11(33.33%) 0.6956
Histologic subtypes Tubular 38 3(7.89%) 1(2.63%) 15(39.47%) 19(50.00%) 0.0005 TvsS<.0001
solid 21 5(23.81%) 6(28.57%) 9(42.86%) 1(4.76%) TvsC0.2075
cribriform 7 2(28.57%) 2(28.57%) 0(0.00%) 3(42.86%) SvsC0.6393
Lung metastasis + 16 8(50.00%) 5(31.25%) 2(12.50%) 1(6.25%) <0.0001
- 50 3(6.00%) 18(36.00%) 12(24.00%) 17(34.00%)
Lymphatic metastasis + 14 8(57.14%) 6(42.86%) 0(0.00%) 0(0.00%) <0.0001
- 52 3(5.77%) 17(32.69%) 14(26.92%) 18(34.62%)
Perineural invasion + 23 9(39.13%) 8(34.78%) 4(17.39%) 2(8.70%) 0.002
- 43 2(4.65%) 15(34.88%) 10(23.26%) 16(37.21%)
TNMstaging T1-2 42 3(7.14%) 6(14.29%) 15(35.71%) 18(42.86%) 0.0235
T3-4 24 7(29.17%) 3(12.50%) 9(37.50%) 5(20.83%)
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spread [18]. MMPs expression in salivary gland cancer
has thus been widely studied, with important findings
that high MMP9 index in ACC was associated with poor
survival [19-21]. Most recently a study suggested that
epithelial-mesenchymal transition (EMT) led to loss of
E-cadherin and gain of vimentin that induces tumor cell
dissemination from the primary tumor site [22]. There-
fore, we compared these molecules in vector or EBP1
stably-transfected ACC-M cell lines. Immunoblot ana-
lysis showed that stable transfection with EBP1 cDNA
significantly reduced expression of MMP9 but boosted
ICAM-1 and E-cadherin protein levels in ACC cells
(Figure 2C and D).
Correlations between EBP1 and MMP9, ICAM-1 and E-
cadherin in ACC patients
Since we had shown that EBP1 regulates the protein levels
of MMP9, E-cadherin and ICAM-1, we detected the
immunoreactivity of MMP9, E-cadherin and ICAM-1 in
the same 132 paraffin-embedded normal adjacent and car-
cinoma tissues as used for immunostaining of EBP1, then
analyzed their correlations to better understand the patho-
physiological and clinical context in which EBP1 might
operate. As shown in Table 3, higher EBP1 expression was
positively correlated with E-cadherin level (P<0.001) but
negatively correlated with MMP9 expression (P=0.0002).
EBP1 has been shown to constitutively activate ICAM-1
transcription [23], and our current results clearly demon-
strated an extensive decrease of ICAM-1 expression in
50/66 ACC tissues. However, statistical analysis shows no
negative correlation between EBP1 and ICAM-1 based on
our current sample size.Survival analysis
Kaplan-Meier survival curves are illustrated in Figure 3.
Log rank tests indicated that a decrease in EBP1 expres-
sion was associated with a reduction in overall survival
of patients with ACC (P<0.0001).
Discussion
ACC is a relentless and unpredictable tumor with a ten-
dency to invade perineural spaces, and is stubbornly re-
current. Eventually, 50% or more widely disseminate to
distant sites such as bone and liver. Thus, although the
5-year survival rate is approximately 60%, it drops to
11% at 20 years [2,3], highlighting the importance of ex-
ploring the underlying molecules associated with recur-
rence and distant metastasis, and the significant
obstacles for the cure of patients with ACC. For the first
time, our current study profiled EBP1 expression in
ACC patients and its clinicopathological relevance.
Mainly, our results demonstrated that EBP1 expression
was inversely correlated with the progression of ACC.
This data is consistent with our previously published
results showing that wild-type EBP1 gene transfer into
human salivary ACC cell line significantly inhibits cell
proliferation in in vitro assays and reduces tumor meta-
static potential in an animal model [11].
Histologically, ACC can be categorized into three
types; tubular, solid and cribriform. The solid pattern is
known to be much more aggressive than the other two
types [24]. Our study showed that EBP1 expression is
significantly higher in cases with tubular pattern than
that with solid pattern. In line with the inhibitory prop-
erty of the EBP1 gene, as previously demonstrated in
cancers of glandular epithelial origin such as prostate
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Figure 2 EBP1 suppresses the motility and invasiveness of ACC-M cells by modulating the expression of invasion-related molecules.
A. Effect of EBP1 on cell migration was investigated using a wound-healing assay, as described in the Materials and Methods. B. EBP1 inhibits the
invasion of ACC-M cells in vitro. Cells that penetrated through the Matrigel to the lower surface of the filter were stained with crystal violet.
Quantification of cells in the lower chamber was performed by counting; the mean number of cells that invaded in three representative fields
per well is expressed; bars, SD. *P<0.05. Data is representative of three independent experiments. C. Protein levels of MMP9, ICAM-1 and E-
cadherin in ACC-M cell line stably transfected with pcDNA 3.1 or pcDNA-EBP1 plasmids were analyzed by western blotting assay, and GAPDH was
used as a loading control. D. Columns represent relative band densities normalized to GAPDH as imaged in A. **P<0.05.
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findings may suggest, at least in part, that a decrease
of EBP1 contributes to the more malignant behavior
of solid type than tubular histotype. Interestingly, in
ACC, EBP1 staining was localized predominantly to
the cytoplasm of epithelial cells of glands, whereas in
the adjacent non-cancerous tissues, abundant EBP1
immunoreactivity was observed in both cytoplasm and
nuclear. Squatrito et al. found that both the N-terminal
and the C-terminal regions of EBP1 are required for
correct EBP1 localization, and that nucleolar localization
is necessary for its growth suppression activity [26].
EBP1 was reported to be mutated in 22% of patients
with colorectal cancers [27]. We are thus poised to exam-
ine EBP1 gene status to determine if EBP1 is a normal
protein in ACC tissues that show strong positive EBP1
staining in the cytoplasm.Insinuate perineural invasion and distant metastasis
are characteristic of clinical features of ACC, and are the
major challenge to very poor long-term outcome of
patients with this disease [1,2,4]. Studies over more than
40 years revealed mounting evidence implicating matrix
metalloproteinases (MMPs) to be the principal media-
tors in the initial proteolytic degradation of extracellular
matrix (ECM) during cancer metastasis [18]. Elevated
levels of MMPs have been associated with the invasive
properties of various cancer types. In particular, high ex-
pression of MMP9 correlates with poor survival of ACC
[19]. In this respect, MMPs might regulate cell-cell and
cell-ECM interactions by processing E-cadherin and in-
tegrin, respectively, affecting both cell phenotype (EMT)
and increasing cell migration [4,18]. Most recently, a re-
port demonstrated that EMT with loss of E-cadherin
and gain of vimentin induces ACC cells to break away
Table 3 Correlation between Ebp1 and MMP9, ICAM-1
and E-cadherin immunostaining intensity in ACC tissues
Variables N
(%)
Ebp1 expression + ++ +++ p-value
-
MMP9
- 1 1 0 0 0 0.0002
+ 1 0 0 1 0
++ 23 3 1 3 16
+++ 41 6 8 20 7
ICAM-1
- 50 8 8 16 18 0.6192
+ 16 2 1 8 5
++ 0 0 0 0 0
+++ 0 0 0 0 0
E-Cadherin
- 1 1 0 0 0 <.0001
+ 24 8 6 10 0
++ 18 1 3 13 1
+++ 22 0 0 1 21
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unique mechanisms of invasion from those of other ma-
lignant tumors of the oral cavity [22]. Nevertheless, we
found that EBP1 inhibits both motility and invasiveness
of ACC cells, further supporting our previous findings
[11]. Importantly, EBP1 downregulates MMP9 but
enhances the protein levels of E-cadherin and another
critical molecule, ICAM-1, which is involved in tumorFigure 3 Disease-free survival in cases with adenoid cystic
carcinoma. Disease-free survival of ACC patients was calculated by
the Kaplan-Meier method. Patients with low or no EBP1 expression
had significantly worse outcomes than patients showing higher
EBP1 staining (P<0.0001, log rank test).immunity and metastasis. Since tumor attack by cyto-
toxic T lymphocytes and macrophages is mediated by
the interaction of leukocyte function-associated antigen
(LFA)-1 on lymphocytes with intercellular adhesion mol-
ecule (ICAM)-1 on the tumor surface [28,29], not sur-
prisingly, reduced expression of ICAM-1 has been
shown to promote immune evasion and metastasis,
resulting in poor prognosis in patients with ACC [30].
Of note, reduced levels of EBP1 expression were sig-
nificantly associated with perineural invasion and local
lymphatic and distant lung metastasis of clinical adenoid
cystic carcinoma. Wild-type EBP1 gene transfer into
ACC-M cells led to reduced motility and invasiveness by
suppressing MMP9 but enhancing protein levels of
ICAM-1 and E-cadherin. Indeed, we found higher EBP1
expression was positively correlated with E-cadherin
level but negatively correlated with MMP9 expression.
Moreover, patients with lower EBP1 had a poorer long-
term survival than those with positive EBP1 expression.
Therefore, EBP1 might be a novel biomarker indicating
local recurrence and distant metastasis, an unfavorable
prognosis in ACC patients. It would be of great interest
to further expand our studies by elucidating how EBP1
downregulates MMP9 but upregulates E-cadherin, given
their therapeutic potential in ACC patients.
Conclusion
EBP1 expression is reduced in ACC, indicating unfavor-
able prognosis of ACC patients. Assessment of EBP1
protein expression status in ACC patients by IHC will
be useful in early detection and prognosis, and therefore
in relevant clinical decision-making such as close moni-
toring as an alternative therapeutic modality against
local invasion and recurrence.
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